^
    Back
    Association details:
    Biomarker:PIK3CA mutation + KRAS mutation
    Cancer:Colorectal Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor) +
    Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO-GI 2023
    Title:

    Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.

    Published date:
    01/17/2023
    Excerpt:
    We explored the in vitro efficacy of drug combinations Ribociclib (R) and Alpelisib (A) in four CRC cell lines with different mutational status; CACO2 (PIK3CA/KRAS wild-type), LS1034 (KRAS mutated), SNUC4 (PIK3CA mutated) and DLD1 (PIK3CA/KRAS mutated)....Drug combination analysis showed that the combination of R and A has a synergistic anti-proliferative effect in all CRC cell lines tested.
    DOI:
    10.1200/JCO.2023.41.3_suppl.167